TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

EXELA HOLDINGS

ImmunologyGastroenterology
Generics

EXELA HOLDINGS is a generic drug manufacturer focused on Immunology, Gastroenterology.

2014
Since
1
Drugs
-
Trials
15
Approved (2yr)

Key Drugs

DICLOFENAC SODIUM AND MISOPROSTOL
diclofenac sodium
Immunology
COX-1 4 indications · 2012

Recent Activity

DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-03-31
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2025-02-27
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2024-12-23
Manufacturing (CMC)
DICLOFENAC SODIUM AND MISOPROSTOL 2024-03-29
Labeling
DICLOFENAC SODIUM AND MISOPROSTOL 2024-03-29
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 50%
1 drugs
Gastroenterology 50%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Immunology, Gastroenterology
BAUSCH specialty
Immunology, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology
Gilead Sciences biotech
Immunology, Gastroenterology